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Biliverdin reductase: a target
for cancer therapy?
Peter E. M. Gibbs, Tihomir Miralem and Mahin D. Maines*
Department of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Biliverdin reductase (BVR) is a multifunctional protein that is the primary source of
the potent antioxidant, bilirubin. BVR regulates activities/functions in the insulin/IGF-
1/IRK/PI3K/MAPK pathways. Activation of certain kinases in these pathways is/are
hallmark(s) of cancerous cells. The protein is a scaffold/bridge and intracellular transporter
of kinases that regulate growth and proliferation of cells, including PKCs, ERK and Akt,
and their targets including NF-kB, Elk1, HO-1, and iNOS. The scaffold and transport
functions enable activated BVR to relocate from the cytosol to the nucleus or to the
plasma membrane, depending on the activating stimulus. This enables the reductase to
function in diverse signaling pathways. And, its expression at the transcript and protein
levels are increased in human tumors and the infiltrating T-cells, monocytes and circulating
lymphocytes, as well as the circulating and infiltrating macrophages. These functions
suggest that the cytoprotective role of BVR may be permissive for cancer/tumor growth.
In this review, we summarize the recent developments that define the pro-growth activities
of BVR, particularly with respect to its input into the MAPK signaling pathway and present
evidence that BVR-based peptides inhibit activation of protein kinases, including MEK,
PKCd, and ERK as well as downstream targets including Elk1 and iNOS, and thus offers
a credible novel approach to reduce cancer cell proliferation.
Keywords: biliverdin reductase, protein kinase C, extracellular signal-regulated MAP kinases, heme oxygenase-1,
oxidative stress, cell cycle
What is BVR?
Some 50 years ago, an enzymatic activity that reduced biliverdin to bilirubinwas described (Singleton
and Laster, 1965; Tenhunen et al., 1970) and subsequently named biliverdin reductase (BVR). Some
years later, highly purified preparations of the rat enzyme revealed a unique profile for the reductase;
at near-neutral pH, the enzyme preferentially uses NADH, while under more alkaline conditions
(pH 8.4) NADPH is the preferred cofactor (Kutty and Maines, 1981). Subsequent studies with
the human and bovine enzymes indicated that the dual pH/cofactor activity profile is preserved in
other mammalian species (Rigney and Mantle, 1988; George et al., 1989; Ding and Xu, 1994), and a
functional reductase has been isolated from cyanobacteria (Schluchter and Glazer, 1997). Advances
in genomic sequencing have revealed the presence of genes encoding the reductase in a wide variety
of vertebrates, including fish, amphibia, reptiles and birds.
Attempts at further characterization of the dual pH/cofactor profile of the enzyme led to a series of
findings indicating a much wider role for the enzyme than had been expected. The protein could be
resolved by isoelectric focusing into multiple variants that were found to arise from phosphorylation
(Huang et al., 1989a,b,c; Huang and Maines, 1990). This in turn led to the observation that BVR is
itself a protein kinase (Salim et al., 2001; Lerner-Marmarosh et al., 2005), and that it belongs to the
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relatively rare class of dual specificity kinases that phosphorylate
tyrosine in addition to serine and threonine.
The primary structure of human BVR harbors an unparalleled
number of functional sequence motifs that enable BVR to act as a
regulator of signal transduction pathways. It contains a bZip DNA
binding sequence, and canonical nuclear localization sequence
(NLS) and nuclear export sequence (NES) that together facilitate
bidirectional nuclear transport of BVR (Lerner-Marmarosh et al.,
2008) and enable it to function as a transcription factor (Ahmad
et al., 2002). There are also sequence motifs that are character-
istic of signal transduction proteins (Gibbs et al., 2012b). BVR
has two consensus Src-homology 2 (SH2) -binding motifs that
resemble binding sites in substrates of the insulin receptor kinase
(IRK); the tyrosine residues in these motifs, Y198 and Y228 in the
YMKM and YLSF motifs, respectively, are targets of IRK (Lerner-
Marmarosh et al., 2005). The SH2 domains were also predicted to
interact with receptors, including the Toll-like membrane glyco-
proteins, via tyrosine-phosphorylated motifs in the latter (Wegiel
et al., 2011). In addition, the observed separation of kinase and
regulatory domains resembles, to some extent, the organization
of the protein kinase C (PKC) isozymes (Newton, 1995). The
dinucleotide/ATP-binding site of BVR (Rossmann fold) is located
in the catalytic domain in the N-terminal region of the molecule
(Whitby et al., 2002). A prominent feature of the C-terminus
is a large six-stranded b-sheet that is a candidate domain for
protein: protein interactions. Additional regulatory sequences are
concentrated in an extended C-terminal a-helix. The regulatory
domain includes two consensus binding sites, the C- and D-Box,
that respectively display high- and low-affinity for kinases in the
mitogen-activated protein kinase (MAPK) pathways (Myers et al.,
1996; Minden and Karin, 1997; Jacobs et al., 1999). The D-Box
of human BVR also overlaps with a Zn(II) binding cysteine-rich
sequence that resembles similar motifs found in the C2 regu-
latory domains of PKCs (Steinberg, 2008; Newton, 2010). This
cysteine-rich sequence also has the potential to respond to the
redox status of the cell, and could function as a signaling switch,
for example in oxidative stress. Each of these motifs has been
implicated in aspects of BVR signaling (Kapitulnik and Maines,
2009; Gibbs et al., 2012b), although each signaling event depends
on a discrete subset of motifs, as would be expected from the
extensive array of pathways where BVR functions. It has become
apparent that thesemotifs are used by BVR tomediate activities of
regulatory protein kinases, although not all kinases are activated
by the same mechanism. Thus BVR can function as a dual-
specificity kinase, as a scaffold independent of kinase function,
and also as a transport protein to translocate other signaling
molecules.
The range of cell signaling functions mediated by BVR is
illustrated in Figure 1. In response to extracellular stimuli, such
as hormones, growth factors or cytokines, two major signaling
pathways are activated, the MAPK and phosphatidylinositide 3-
kinase (PI3K) pathways. As will be discussed, BVR activates
kinases in both pathways, with the end result being expression of
genes that are involved in cell growth, differentiation and survival.
This, in turn, suggests that BVR is of direct relevance in cancer
development, where unimpaired cell proliferation is the common
outcome.
FIGURE 1 | (A) Simplified representation of the two major arms of signal
transduction from cellular receptors, in particular, those for insulin and growth
factors. Solid arrows indicate reactions wherein BVR has been demonstrated
to act as a scaffold, molecular bridge, intracellular transporter, transcription
factor or kinase. In the case of activation of VEGF expression by ERK1/2
and/or PKCd, this follows as a consequence of BVR-dependent stimulation of
kinase activities. (B) Three mechanisms of BVR function as a cytoprotectant.
The reductase activity converts biliverdin to the antioxidant bilirubin. In
addition, biliverdin is a known inhibitor of PKCd (Miralem et al., 2012) and of
NF-kB (Gibbs and Maines, 2007).
Each of the extracellular stimuli acts by binding to a cell
surface receptor, resulting in transduction of a signal through
the cell membrane. In the case of insulin and insulin-like
growth factor-1 (IGF-1), this activates a kinase domain located
on the cytoplasmic surface of the membrane, triggering cas-
cades of downstream signals. It was demonstrated that IRK
can use BVR as a substrate (Lerner-Marmarosh et al., 2005),
and in turn BVR is able to phosphorylate insulin receptor
substrate-1 (IRS-1), a major IRK substrate that acts to limit
glucose uptake in response to insulin. Overexpression of BVR
itself results in diminished glucose uptake, presumably mediated
by the phosphorylation of IRS-1, whereas increased uptake is
observed after treatment with small interfering RNA (siRNA)
to attenuate cellular BVR levels (Lerner-Marmarosh et al.,
2005).
Here we discuss how BVR and its signaling is integrated into
carcinogenesis and cancer progression, and how peptides, based
on well characterized motifs in human BVR, most likely will be
of use in cancer prevention or suppression. Two major pathways
that regulate cell proliferation survival and invasion, i.e., Ras-
MAPK and PI3K, play central roles inmultiple processes in cancer
(Malumbres and Barbacid, 2003). Both cascades have input from
BVR at multiple steps, and the modes of activation by BVR will be
discussed.
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BVR in Cancer
Cancer is a heterogeneous group of disorders that are character-
ized chiefly by unconstrained cell replication, and by invasiveness
of the cancer cells that eventually enables them to metastasize
throughout the organism. Cancers arise as the end result of accu-
mulated genetic and epigenetic adaptations that enable cells to
escape the homeostatic controls that ordinarily suppress cell pro-
liferationwhile inhibiting survival of aberrantly proliferating cells,
although the breakdown in control is not identical in all cancers
(Evan and Vousden, 2001). These adaptations may occur in any of
a variety of signaling pathways, such that the etiology of two given
tumors may be completely different. In addition to these changes,
progression of the cancer is associated with a complex interplay
among tumor cells, the surrounding non-neoplastic cells and the
extracellular matrix (Leber and Efferth, 2009). The tumor cells
develop several novel features, including hyperproliferation, resis-
tance to apoptosis, metabolic changes, genomic instability, induc-
tion of angiogenesis and increased migration (Leber and Efferth,
2009). Most of these characteristics are regulated by cellular signal
transduction. Aberrant signaling in pathways that are intimately
involved in embryogenesis and adult tissue homeostasis, such as
those regulated by the extracellular ligands Wnt and Hedgehog,
or by the cell surface receptor Notch, have been definitively asso-
ciated with initiation and progression of tumorigenesis (Jiang and
Hui, 2008; Klaus andBirchmeier, 2008; Sethi andKang, 2011). The
cytokine tumor-derived growth factor-b exerts paradoxical effects
on cells—it acts as a tumor suppressor, such that transformation
necessitates evasion of the cytokine, but at the same time may
mediate changes in the microenvironment of the cell to facilitate
invasiveness and in suppression of the immune system, both of
which would be expected to promote tumor growth (Massague,
2008; Inman, 2011). It is beyond the scope of this review to
discuss these pathways in detail and currently the relevance of
BVR in any of the pathways is tenuous at best. Rather, we will
focus on the pathways that converge on the extracellular-signal-
regulated kinases 1 and 2 (ERK1/2), for which a considerable body
of evidence has accumulated indicating that BVR is a regulator
of their activation. Other points of discussion will include the
role of BVR in the PI3K/Akt pathway, and its effects on NF-kB
(nuclear factor k-light-chain-enhancer of activated B cells), both
of which are relevant to the etiology and maintenance of cancer
cells. It should also be noted, however, that there is considerable
cross-talk among all of the pathways, such that Akt functions
in Wnt signaling, although there is evidence to suggest that the
mechanism differs between normal and tumor cells (Anderson
andWong, 2010), and the smad2 and smad3 proteins in the TGF-b
pathway are activated by ERK (Hough et al., 2012). The relevance
of BVR may not, therefore, be entirely limited in scope.
As shown in Figure 2, overexpression of BVR leads to changes
in cell morphology. In Figure 2A, the transfected cells appear to
be flattened, andmore spread out on the plate. This is also evident
in Figure 2B, where transfected cells overexpressing BVR are seen
on a background of untransfected cells, which display a more
rounded morphology. Moreover, it was observed that in renal
tumors, BVR was both overexpressed and located predominantly
in the nucleus (Figure 3; Maines et al., 1999). Elevated BVR
FIGURE 2 | Morphology of cultured cells with overexpressed BVR.
(A) HEK cell transfected with an EGFP-BVR fusion plasmid shows a flattened
morphology atypical of the parent cell line. Adapted from (Maines, 2005).
(B) Similarly, HeLa cells transfected at low efficiency with a human BVR
expression plasmid and analyzed by immunohistochemistry with antibody
against BVR are apparently enlarged relative the surrounding lawn of
untransfected cells.
FIGURE 3 | Immunohistochemical detection of biliverdin reductase in
normal human kidney cells and in a kidney tumor. Note that the
magnification of the normal kidney is 10-fold greater than that of the tumor.
Modified from (Maines et al., 1999).
expression was not limited to the tumor cells as such, but
was also seen in infiltrating T-cells, monocytes, macrophages
and lymphocytes. Increased BVR was also seen in circulating
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lymphocytes from the same patient. It was also noteworthy that
reductase activity in tissue extracts was increased in the tumors;
however, this was dependent on the assay. The activity was
increased twofold if NADH (at pH 6.7) was used as cofactor,
while there was minimal change with NADPH at pH 8.4. These
observations offer a potential explanation of the elevated levels of
heme oxygenase-1 (HO-1) seen in prostate cancers as first noted
by (Maines and Abrahamsson, 1996). In this early study, HO-1 in
normal prostate tissue is expressed in the stroma, and the epithelial
layers of acini and ducts. Benign prostate hyperplasia show
elevatedHO-1, particularly in the basal layers of epithelia, whereas
in undifferentiated prostate cancer, all cells, including those of
blood vessels, show high HO-1. The constitutively expressed
HO-2 showed no change in expression. These observations have
been confirmed and extended, further demonstrating that HO-1
localizes in the nuclei of prostate tumor cells, and counters, in part
at least, the activation and/or expression of proteins involved in
neovascularization (Sacca et al., 2007; Ferrando et al., 2011, 2013;
Biswas et al., 2014). It is tempting to speculate that the elevated
expression of HO-1 could be a consequence of elevated BVR
levels, since BVR has been shown to play a role in HO-1 induction
(Ahmad et al., 2002; Kravets et al., 2004; Miralem et al., 2005;
Tudor et al., 2008). However, some prostate cancers have recently
been shown to have elevated levels of flavin oxidase (Pallua
et al., 2013). This enzyme (also known as biliverdin reductase
B, BVR-B) is unrelated to BVR (as used in the context of this
review), but is the primary source of bilirubin in the fetus. As
such, the increased expression could reflect the tumor cells being
at a very primitive stage of differentiation. Alternatively, it could
reflect the hypoxic state of the tumor; BVR-B was over-expressed
in skeletal muscle of members of an expedition toMt Everest after
19 days of the low O2 pressure characteristic of 5300 m above
sea level (Levett et al., 2014). Other than being a possible source
of bilirubin, the relevance of this enzyme to cytoprotection in
cancer and the functions of BVR in general, is unclear.
The possibility that BVR expression levels could be used as
a biomarker of certain cancers (Hellman et al., 2009) was sug-
gested by proteomic approaches that compared proteins in biop-
sies obtained from normal vaginal epithelium, primary vaginal
carcinomas and primary cervical carcinomas. Significantly altered
expression of 43 proteins was observed between the tumors
and non-tumor tissue, with 26 of these being up-regulated and
the remaining 17 down-regulated. Expression of three proteins,
erbB3-binding protein, the helicase DDX48 and BVR was found
to be altered solely in vaginal carcinomas and therefore were
proposed as useful molecular markers for this carcinoma. The
elevated levels of BVR in tumor cells is predictably due to a cancer-
related hypoxia, as it was shown that BVR gene expression can
be induced in hypoxic HEK293 cells or in cells over-expressing
the HIF1 transcription factor (Gibbs et al., 2010). Similarly,(Song
et al., 2013) have shown that in pulmonary arterial smoothmuscle
cell (PASMC) apoptosis is inhibited by hypoxia, and BVR pro-
tein and mRNA levels were upregulated. Treatment of PASMC
with siRNA against BVR led to increases in markers of apoptosis
(Song et al., 2013). Furthermore, these effects could be reversed
with bilirubin, which could itself block apoptosis if the ERK1/2
pathway was active. It is noted that hypoxia induces alterations in
the cellular redox status, which in turn plays a critical role in the
subsequent development of resistance to chemotherapeutic agents
in cancer cells. BVR expression in human glioblastoma cells was
significantly increased in response to hypoxia (Kim et al., 2013).
In contrast, the hypoxia-induced chemoresistance in these cells
could be attenuated by treatment with siRNA against BVR, which
led to significantly increased levels of intracellular reactive oxygen
species (ROS). Pretreatment of the cells with the antioxidant N-
acetylcysteine reversed the sensitivity to chemotherapeutics seen
in BVR-depleted cells. Enhanced activity of BVR also protected
cells from treatment with genotoxic anti-cancer drugs such as
cisplatin or doxorubicin (Florczyk et al., 2011). This effect pre-
dictably could be linked to activation of PKCs a and b, as BVR
inhibition reversed the protection (Florczyk et al., 2011). The
activity of BVR thuswould influence the effectiveness of therapies.
It is noted that this is a narrow range of studies, and that while
there is a correlation of overexpression of BVR and tumor growth,
one cannot distinguishwhether the elevated BVR levels are a cause
or an effect of the cellular reprogramming that occurs in cancer.
That may not however, disqualify BVR as potential target for
therapy.
Given the nuclear localization of BVR seen in kidney tumors
(Maines et al., 1999), and its ability to activate transcription factors
linked to cell growth, this result is a tempting indication of BVR
perhaps being directly involved in tumor cell growth. In this
respect, it is worth noting that overproduction of BVR results in
significant changes in expression of cell cycle genes (Table 1),
including transcription factors, genes involved in chromosome
replication and cyclin-dependent kinases, while expression of
two check-point inhibitor protein genes are significantly down
regulated (Kravets et al., 2004). These findings indicate a role
for BVR regulation of the cell cycle. This either occurs directly
due the pronounced relocation of BVR to the nucleus (Figure 3),
or indirectly by activation of upstream pathways that themselves
activate the cell cycle (Figure 4).
TABLE 1 | Cell proliferation genes activated by over-expressed BVR.
Gene name Fold-change
Cullin-1 (CUL-1) 107
Mini-chromosome maintenance-3 (MCM3) 21.3
Cell division cycle 25 homolog A (CDC25A) 15.8
E2F transcription factor-3 (E2F-3) 13.5
Ring-box protein-1 RBX1) 8.6
Proliferating cell nuclear antigen (PCNA) 7.0
Cyclin-dependent kinase-2 (CDK2) 4.9
Cyclin-dependent kinase-4 (CDK4) 4.0
CDK inhibitor 2B (CDKN2B) p15  2.5
CDK inhibitor 1B (CDKN1B) p27KIP  5.0
Cells were treated with adenovirus expression vector encoding human BVR regulated by
a Tet promoter (Kravets et al., 2004) and BVR expression was induced by treatment with
doxycycline for 16 h. Total RNA was analyzed using a microarray to detect expression of
genes involved in cell proliferation. Genes that showed a significant deviation in expression
in cells with elevated BVR compared to untreated cells are indicated. Modified from
(Kravets et al., 2004).
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FIGURE 4 | BVR targets in cell cycle activation. Signaling
pathways that directly activate the cell cycle and themselves activated
by BVR are shown. Those proteins that are activated by BVR or
whose levels are modulated by overexpression of BVR (such as the
cyclins, CDKs, and CDK inhibitors, as described in Table 1) are
indicated by bold arrows.
BVR Activity in the MAPK Pathway
Environmental stimuli, including growth factors, cytokines and
hormones, as well as stress due to heat or altered redox status of
the cell (Cobb and Goldsmith, 1995; Jackson and Foster, 2004;
Boutros et al., 2008; Kim and Choi, 2010) stimulate receptor com-
plexes (receptor tyrosine kinases, G-protein coupled receptors),
that in turn recruit either PI3K or son of sevenless (SOS) and the
growth factor bound-2 protein (GRB2), potentially activating two
major signaling branches. Constitutively active receptor tyrosine
kinases, including those of epidermal growth factor, fibroblast
growth factor and platelet-derived growth factor receptors that
are frequently found to be mutated or up-regulated in a variety
of cancer types. Activation of SOS and GRB2 leads to exchanging
Ras-bound GDP for GTP to yield the active form. The activated
GTP-Ras complex then interactswith a variety of effector proteins,
including members of the Raf kinase family (Vojtek et al., 1993;
Geyer and Wittinghofer, 1997). Raf activation in the cell occurs
in the presence of activated GTPases, such as the Ras family
of proteins, which allow translocation of the Raf protein to the
membrane, binding of Raf to Ras (Terai and Matsuda, 2005), and
subsequent homodimerization or heterodimerization with the
kinase suppressor of Ras (KSR) protein (Brennan et al., 2011). The
dimers at this stage are partially active, but transphosphorylate
other dimers to give a fully active MAPKKK enzyme (McKay
et al., 2011). The Raf proteins then phosphorylate the MAPKK
proteins, including MEK1 and MEK2. The activated MEK pro-
teins then phosphorylate the sequence TXY in MAPKs (TEY
in ERK1/2) thereby activating these serine/threonine kinases.
There are three subfamilies that comprise the MAPK family of
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protein—the extracellular response kinases (ERK1, ERK2 and
the more distantly related ERK5), the p38 MAPKs and the c-
Jun N-terminal kinases (JNKs). Phosphorylation of SP or ST
sequences in the extensive range of MAPK substrates regulates
cellular functions that include metabolism, gene expression, cell
proliferation, movement and differentiation, and programmed
cell death reviewed in Mebratu and Tesfaigzi (2009).
ERK1 (MW 44 kDa) and ERK2 (42 kDa) share85% sequence
identity, with functional of the protein being more highly con-
served, and are expressed ubiquitously (Boulton et al., 1991). As
would be expected given this high degree of sequence similarity,
they largely share the same substrates. Gene knockout studies
have indicated that the ERK isoforms have different functions in
embryonic development. ERK2 and MEK 1 are essential, and the
knockouts show impaired placental development (Giroux et al.,
1999; Hatano et al., 2003); by contrast, ERK1 or MEK2 knockouts
were phenotypically normal with respect to size, fertility and
viability (Pages et al., 1999; Belanger et al., 2003).
In resting cells, ERK is sequestered in the cytoplasm. This
sequestration is mediated by multiple mechanisms, including
association with MEK (Fukuda et al., 1997), with microtubule
structures (Reszka et al., 1995) or with phosphatases, such as the
MAP kinase phosphatase MKP3 which complexes with ERK1/2,
and by virtue of its NES confines ERK to the cytoplasm (Karlsson
et al., 2004).Mitogen stimulation results in rapid (5–10min) burst
of kinase activity, followed by transit to the nucleus, and a more
sustained, albeit lower, level of activation that persists through
G1 until entry into S-phase (Kahan et al., 1992; Meloche et al.,
1992; Meloche, 1995), whereupon ERK is rapidly inactivated.
While ERK activity is essential for the G1-S phase transition, it
is not sufficient (Kahan et al., 1992). There is evidence to suggest
that prolonged activation of ERK might be proapoptotic, whereas
transient activation is cytoprotective (di Mari et al., 1999; Arany
et al., 2004).
Experiments carried out in vitro and in intact cells, indicated
that BVR activated both MEK1 and ERK1/2, with the three pro-
teins forming a ternary complex (Lerner-Marmarosh et al., 2008).
Over-expressed BVRwas almost as effective as IGF-1 in activating
ERK1/2 in cultured cells; BVR is itself a substrate for the ERK1/2
kinase activity. Formation of the MEK/ERK/BVR ternary com-
plexwas impaired in cells treatedwith siRNAagainst BVR, leading
to decreased activation of ERK1/2 in response to IGF-1. Although
ERK1/2 is not a substrate for BVRkinase activity, theATP-binding
domain of BVRwas shown to be necessary for ERK1/2-dependent
Elk activation, although ERK1/2 is not phosphorylated by BVR
(Lerner-Marmarosh et al., 2008).
Translocation of ERK to the nucleus is essential for its effects on
regulating gene transcription, and would therefore be a potential
target for mediating its growth promoting properties. ERK1/2 are
transcriptional regulators of over 50 genes, including c-jun, c-
fos, Myc, NF-kB, iNOS, NR2F, Bach1 GATA1, STATs, HIF1, and
VEGF (Giuliani et al., 2004; Ranganathan et al., 2006; Yoon and
Seger, 2006; Yazicioglu et al., 2007) that control cell polarity,
proliferation, differentiation, adhesion, and invasiveness.We have
described BVR-mediated ERK transport to the nucleus, and its
inhibition by peptide(s) that disrupt BVR-ERK complex forma-
tion and activation of ERK (Lerner-Marmarosh et al., 2008). ERK
signaling activates transcription factors including Elk1 that in turn
regulate the cell cycle. However, the kinases also inactivate com-
ponents of the cell death pathways, and stimulate transcription of
genes that promote cell survival. Thus phosphorylation by ERK
of the FOXO transcription factors promotes their degradation
by MDM2-dependent ubiquitination and proteasomal mecha-
nisms. FOXO-dependent transcription targets include antiapop-
tosis genes such as those encoding Bim or FasL (Burgering and
Kops, 2002; Finnberg and El-Deiry, 2004), as well as cell cycle
regulators such as cyclin D (Schmidt et al., 2002) and p27/Kip1
(Dijkers et al., 2000). It is noted (Table 1) that p27/Kip1 expres-
sion is significantly repressed when BVR is over-expressed. Thus
inhibition of ERK activity, e.g., by the C-box peptide, would be
expected to inhibit cell proliferation as a consequence of stable
FOXO-dependent transcription.
There are twoMAPKconsensus dockingmotifs in humanBVR:
the C-Box (Jacobs et al., 1999) 162FGFP and D-Box (Minden and
Karin, 1997) 275KKRILHCLGL. Both are required for assembly
of the ternary complex with MEK1 and ERK2, since BVR bear-
ing mutations in either motif inhibits activation of ERK1/2 in
response to IGF-1 treatment, leading to a significant reduction in
Elk1-dependent transcriptional activity (Lerner-Marmarosh et al.,
2008). Similar observations were made with cells treated with
BVR-based peptides bearing the C- or D-Box sequences (Lerner-
Marmarosh et al., 2008). ERK1/2 transport into the nucleus
was impaired in cells expressing the BVR NLS mutant; likewise,
nuclear accumulation of ERK1/2 was observed in cells expressing
the NES mutant (Lerner-Marmarosh et al., 2008). Taken together,
these observations indicate that BVR is a bidirectional trans-
porter of ERK1/2 between the cytoplasm and nucleus. This is a
most significant aspect of BVR’s cellular function, since ERK1/2
relies on transporter proteins to shuttle between the nucleus and
cytoplasm, as it does not possess either NLS or NES motifs.
The ribosomal S6 kinase (RSK) family of protein kinases is
activated by ERK, resulting in translocation of RSK, at least in part,
to the nucleus (Zhao et al., 1996. The proapoptotic BAD protein
is phosphorylated by RSK resulting in its inactivation (Bonni
et al., 1999, Anjum and Blenis, 2008). In addition, the survival-
promoting transcription factor ATF2/CREB is phosphorylated
and activated by RSK (Bonni et al., 1999). It is noteworthy in this
context that ATF2/CREB is also activated by overexpression of
BVR (Kravets et al., 2004; Miralem et al., 2005).
A second, prominent transcription factor target of ERK is
c-Myc; phosphorylated c-Myc is stabilized as the modification
blocks ubiquitination and hence proteasomal degradation (Sears
et al., 2000). cMyc is frequently activated or mutated in an exten-
sive variety of cancer cell types, where it induces expression of
genes involved in cell proliferation, including cyclins, CDKs and
transcription factors, while simultaneously blocking expression of
cell cycle inhibitors (Duronio and Xiong, 2013). It is noteworthy
that these genes resemble the cell-cycle genes whose expression
was altered by over-expressing BVR (Table 1). It is tempting
to speculate that overexpressed BVR targets ERK-dependent c-
Myc activation to produce the observed transcriptional profile
changes.
In addition, activation of the MAPK family proteins leads
to phosphorylation and subsequent polyubiquitination and
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proteasomal degradation of the pro-apoptotic protein Bim (Hub-
ner et al., 2008). Because phosphorylated Bim is bound less well by
the antiapoptotic Bcl2 protein compared to its unphosphorylated
form, the net result of its phosphorylation in response to ERK
pathway activation is increased cell survival (Ley et al., 2003,
2004). Bcl2 gene expression is enhanced by overexpression of
BVR (Kravets et al., 2004). These and other studies are indica-
tive of ERK promotion of resistance to apoptosis; BVR itself has
been shown to contribute to resistance to chemically-induced cell
death, whether in the context of cancer therapy or oxidative stress
inducing compounds such as arsenite (Miralem et al., 2005).
The Ras family comprises some of the earliest identified onco-
genes; they were initially described as the transforming gene in
oncogenic viruses or in tumors (Malumbres and Barbacid, 2003).
Constitutively active Ras mutants that do not exchange bound
GTP have been identified in about 30% of all tumors, although
they aremore prevalent in some tumor types than in others Persis-
tent activation of ERK by mutated Ras or Raf proteins contributes
to tumor cell proliferation; indeed the transforming potential of
Ras or Raf mutants is absolutely dependent on the downstream
MEK and ERK proteins, thus providing an impetus for develop-
ment of inhibitors of MEK or ERK (Kohno and Pouyssegur, 2003)
as therapeutic agents. It is still an unresolved issue as to whether
such inhibitors will be useful in the clinical setting. Despite a
massive effort in developing such drugs (Chappell et al., 2011),
their efficacy in clinical trials has been sadly lacking (Haura et al.,
2010). It could be argued that prevention of ERK translocation
might be an efficient means of enhancing those functions of ERK
that promote cell death, thereby killing tumor cells and controlling
cancer development. In normal cells, activated ERK proteins in
turn phosphorylate Raf, leading to its inactivation, and quench-
ing the signaling pathway. Breast tumor cells, for example are
characterized by dysfunction of the Ras-Raf-MEK-ERK pathway;
indeed, the activity of this pathway is increased in one-third of all
human cancers (Roskoski, 2012). Activation/phosphorylation of
ERK1/2 is correlated with both poor therapeutic response to anti-
hormonal drugs and with decreased survival rate in breast cancer
patients (Gee et al., 2001).
BVR, ERK1/2, PKCd—the Complex
PKCd functions in multiple signaling pathways, in particular,
those that lead to ERK1/2 activation (Gorelik et al., 2007). More-
over, there is evidence that PKCd activates ERK proteins directly
(Ueda et al., 1996). PKCd is a member of the novel class of
PKCs and a key regulator of pathways that control cell growth
and proliferation (Steinberg, 2004); however, it also regulates cell
division arrest and is involved in glucose signaling (Steinberg,
2008; Newton, 2010). Whether the PKC regulates apoptotic or
anti-apoptotic signaling pathways depends on its mode of acti-
vation in response to specific stimuli. PKCd is activated by BVR
in autophosphorylation and kinase assays. While PKCd utilizes
BVR as a substrate (Gibbs et al., 2012a), PKCd was not a substrate
for BVR kinase activity in vitro. Addition of either wt- or kinase-
inactive BVR stimulated PKC activity toward a peptide substrate
(Gibbs et al., 2012a). Amutant of PKCd that lacks part of the pseu-
dosubstrate sequence is constitutively active (Zhao et al., 1998),
and this proteinwas also showed increased activity in the presence
of BVR (Miralem et al., 2012). The increased activity of PKCdwas
dependent on complex formation with BVR. Proteomic analyses
indicated that human BVR was phosphorylated by PKCd at four
serine residues, with two of those sites, Ser21 and Ser230, being
kinetically favored (Miralem et al., 2012). Indeed, a 13 aa peptide
that includes Ser230 and its flanking sequence was found to be an
excellent substrate for PKCd in in vitro assays. Phosphorylation at
either Ser33 or Ser237 was not predicted by computational analysis,
and the observed result suggests that they are likely novel PKCd
targets (Miralem et al., 2012).
A complex containing both BVR and PKCd was observed
in immunoprecipitates obtained from either PMA- or IGF-1-
treated cells (Gibbs et al., 2012a). In vivo association between
the proteins was demonstrated by fluorescence resonance energy
transfer (FRET). FRET was as detected by fluorescence lifetime
imaging microscopy (FLIM); a reduction in fluorescence lifetime
in this system indicates that FRET has occurred. Cells cotrans-
fected with EGFP-PKCd and DsRed2-tagged BVR fusion proteins
were treated with either IGF-1 or PMA and reduced fluorescence
lifetime was observed in the cotransfected cells compared to
cells transfected with EGFP-tagged PKCd alone, for either IGF-
1 or PMA-treated cells (Gibbs et al., 2012a,b); the positive FRET
response indicates a close intracellular association of the proteins.
A requirement for the human BVR KKRILHCLGLA sequence
for interaction with PKCd was revealed by the observations that
a protein carrying mutations in this motif and a peptide with
the wt sequence both inhibited the protein: protein interaction.
The likelihood is that binding of the PKC to BVR triggers a
conformational change in the former to facilitate its activation,
thereby positioning BVR for an important role in another pathway
leading to tumorigenesis.
The observation that BVR is detected in complexes with
ERK1/2 and MEK1/2 (Lerner-Marmarosh et al., 2008), and with
PKCd raised the question of whether BVR and its binding partners
might form a larger macromolecular signaling entity. Cells over-
expressing both BVR and PKCd and subsequently stimulated with
PMA or IGF-1 were found to include both ERK2 and MEK1 in
immunoprecipitates obtained with anti-BVR or anti-PKCd anti-
bodies (Gibbs et al., 2012a). It is possible that there could be inde-
pendent cytoplasmic ternary complexes, depending on whether it
is MEK1/2 or PKCd that is activating ERK1/2. Cells were trans-
fected to over express BVR and PKCd, treated with IGF-1 and
complexes were immunoprecipitated from cell lysates with anti-
PKCd antibodies. MEK1 was detected in the immunoprecipitate,
togetherwith BVRandERK2. Since all four proteinswere detected
in a single immunoprecipitation, it is apparent that an elaborate
signaling complex is formed (Gibbs et al., 2012a). Unconstrained
activation of ERK by this multiprotein complex is expected to be
harmful to the cell, since it would deregulate gene expression and
also cell proliferation. Apparently, the complex also contained the
protein phosphatase PP2A (Gibbs et al., 2012a) that targets, and
inactivates, PKCd (Srivastava et al., 2002), suggesting amechanism
that would prevent “runaway” signaling by the ERK1/2 complex
that essentially involves its self-regulation. As BVR’s kinase activ-
ity was not needed for complex formationwith PKCd, BVR ismost
likely acting as a scaffold to bring the substrate ERK2 into close
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proximity with its activating PKC or MEK, while maintaining the
proteins in their active conformation. Site-directed mutagenesis
indicated that complex formationwas dependent upon intact BVR
C- and D-Box sequences. ERK2 was recruited to the complex by
the C-Box, while PKCd interacted with the D-Box. Treatment of
cells with synthetic peptides that include the human BVR C- and
D-Box sequences inhibited complex formation. Activation of the
transcription factors Elk1 andNF-kB is dependent on ERK activa-
tion, while disruption of complex formation by siRNA-mediated
depletion of BVR led to attenuated transcriptional activity and
expression of reporter genes (Gibbs et al., 2012a). The NF-kB-
dependent activation of the iNOS promoter is also dependent on
complex formation—ablation of any one of BVR, PKCd, ERK1/2,
or MEK1/2 with the appropriate siRNA suppressed reporter gene
expression driven by the iNOS promoter (Gibbs et al., 2012a).
These findings imply a second mechanism by which BVR acts
in protection against oxidative stress (Miralem et al., 2005). The
significance of BVR/PKCd binding can be considered in the con-
text of PKC functions in the cell: It is noted that PKCd is involved
in pathways that regulate cell cycle progression resulting in cell
proliferation, differentiation or tumorigenesis (Steinberg, 2008;
Newton, 2010). Oxidative stress, however, results in PKCd being
a major factor in activation of mitochondrial-linked apoptosis
pathways that lead to cell death (Buder-Hoffmann et al., 2009).
In this response, caspase3 cleaves the PKC into regulatory and
catalytic domains (Steinberg, 2008), and it is the unregulated
catalytic domain that is linked to PKCd-mediated cell death. It is a
reasonable suggestion that the BVR/PKCd complex blocks access
of caspase3 to the PKC, thereby attenuating the onset of apoptosis.
In addition to the hyper-activation of PKCd and ERK1/2 sig-
nals, over-expression of BVR leads to effects on other gene tar-
gets. Thus in cells over-expressing BVR, there is a demonstrable
increase in the activity of NF-kB, as indicated by expression of
reporter genes (Figure 5A). The increased activity is entirely
dependent on BVR, as shown by the ability of siRNA against
BVR to block PKCd-dependent activation of NF-kB (Figure 5B).
Likewise, tumor necrosis factor-a (TNF-a) dependent induction
of transcription of a reporter gene regulated by the promoter
for the inducible nitric oxide synthase (iNOS, encoded by the
NOS2 gene) is further increased in cells that over-express BVR
(Figure 5C). These data imply that over-expressed BVR is capable
of stimulating pro-survival genes.
PKCd activity is upregulated in breast and lung cancers (Clark
et al., 2003; McCracken et al., 2003) and its expression is
stimulated by estrogens, thus contributing to resistance to the
chemotherapeutic tamoxifen (Cutler et al., 1994; Nabha et al.,
2005). Despite the protection afforded by BVR regulating the
levels of the antimutagenic bile pigments (Bulmer et al., 2007),
BVR is likely to be a contributing factor in the development of
cancers, since BVR activates both proteins (Lerner-Marmarosh
et al., 2008; Gibbs et al., 2012a; Miralem et al., 2012).
BVR Modulation of the PI3K/Akt Pathway
The PI3Kpathway regulates cell survival (Amaravadi andThomp-
son, 2005), while in turn, Akt activity is inhibited by ERK (Sinha
et al., 2004), so that in primary cells where ERK activation is
FIGURE 5 | BVR enhances ERK1/2-dependent transcriptional
activation. (A) NF-kB-dependent promoter activity is stimulated by BVR.
Cells were cotransfected with a luciferase reporter plasmid regulated by
NF-kB, a b-Gal reporter (to serve as a control for transfection efficiency), and
either pcDNA-hBVR or empty vector. 24 h later, NF-kB-dependent promoter
activity was measured by luciferase assay and normalized to b-galactosidase.
Modified from (Gibbs and Maines, 2007). (B) BVR-siRNA suppresses
activation of NF-kB by PKCd. Cells were cotransfected with NF-kB and b-gal
reporters, pcDNA-PKCd and siRNA for BVR or control scRNA. Promoter
function was analyzed as in (A), *p < 0.001. Modified from (Gibbs et al.,
2012a). (C) TNF-a-mediated induction of the iNOS gene is potentiated by
BVR. Cells were cotransfected with pcDNA3-hBVR, a luciferase reporter
plasmid wherein luciferase is regulated by the iNOS promoter, and b-gal
reporter. 12 h after DNA addition, cells were treated with TNF-a for a further
12 h. Promoter function was then analyzed as in (A). Modified from (Gibbs
and Maines, 2007).
suppressed, this feedbackmechanism enhances cell survival. Con-
versely, activation of Akt by PMA or EGF inhibits Raf activity
and hence the ERK pathway is also inhibited. Nonetheless, over-
expression of Akt does not affect ERK phosphorylation (Gervais
et al., 2006). ERK phosphorylation in these circumstances might
be more dependent on PKCd (Ueda et al., 1996; Gorelik et al.,
2007). However, the activated ERK is sequestered in the cyto-
plasm by binding to the Akt substrate PEA15, preventing Elk1-
dependent transcription and expression of cFos (Gervais et al.,
2006). PI3K-Akt signaling controls cell proliferation by regulating
the cell cycle as mediated by mTORC1 (Bhaskar and Hay, 2007),
phosphorylating GSK3 to inhibit its catalytic activity (Clodfelder-
Miller et al., 2005) and by suppressing the cell cycle inhibitors
p27 and p21 (Abukhdeir and Park, 2008), thereby stabilizing
important cell cycle regulators. Aberrant activation of the pathway
is a mechanism for carcinogenesis (Bhaskar and Hay, 2007). As
with the MAPK pathway, there is evidence that BVRmay regulate
key points in this pathway.
It was proposed that BVR might function in the PI3K/Akt
pathway based on its two SH2-binding motifs (Maines, 2007).
While these are key to interaction with IRK, they should also
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be able to mediate binding to PI3K. Ischemia/reperfusion injury
is characterized by oxidative stress, and in a cell culture model
it was noted that phosphorylation of both the regulatory p85
subunit of PI3K and Akt was increased during BVR-dependent
HO-1 overexpression, which in turn afforded protection against
apoptosis (Pachori et al., 2007). Akt phosphorylation depended
on PI3K, which acts upstream of Akt in the signaling pathway,
because siRNA-mediated knockdown of PI3K abolished cyto-
protection. BVR and the phosphorylated p85 subunit of PI3K
were observed to coimmunoprecipitate. Because Akt phosphory-
lation was also attenuated in cells treated with siRNA directed
against BVR, it is likely that BVR is a cytoprotective signaling
protein, by virtue of its activation of the PI3K pathway in response
to oxidative stress (Pachori et al., 2007). Likewise, upregula-
tion of BVR expression in a human renal proximal tubule cell
line was observed after the cells were incubated at low oxygen
concentration (Zeng et al., 2008). The BVR promoter is acti-
vated during prolonged hypoxia (Gibbs et al., 2010), which is
expected to increase BVR protein content in the cell and thus
affect its function in cell signaling. In a second model of oxidative
stress, it was observed that knockdown of BVR, again by the
use of siRNA, rendered cells more vulnerable to sodium arsenite
treatment—a higher proportion of apoptotic cells was observed
among those treated with siRNA and arsenite compared to those
treated with arsenite alone (Miralem et al., 2005). Moreover, renal
failure in response to chronic hypoxia results in an epithelial-
to-mesenchymal transition (EMT), characterized by decreased
expression of E-cadherin and increased expression of vimentin, a
diagnostic marker of mesenchymal cells (Zeng et al., 2008). These
changes in gene expression were prevented when PI3K activity
was inhibited. BVR’s role as a causative factor for these changes
is further demonstrated by the observation that its overexpression
in normoxic cells led to EMT-like phenotypic changes, and that
PI3K inhibition reversed the effects (Zeng et al., 2008). In these
cells, PDK1-dependent phosphorylation of Akt was dependent
on PI3K activity and BVR was associated with the activated,
phosphorylatedAkt. Blockade of this associationwith BVR siRNA
effectively prevented EMT, reinforcing the strong connection of
BVR to this cascade.
It has been suggested that BVR is expressed on the exterior
surface ofmacrophages (and other cells) where reduction of extra-
cellular biliverdin to bilirubin initiates a cascade mediated by
tyrosine phosphorylation of BVR (Wegiel et al., 2009). In turn,
phosphorylated BVR binds to the regulatory p85a subunit of
PI3K to activate signaling via Akt. Bacterial endotoxin was used
to initiate the inflammatory response cultured in macrophages,
resulting in a rapid rise in BVR activity. It was suggested that
biliverdin mediated its protective effects through induction of
synthesis of the anti-inflammatory cytokine, interleukin-10 (IL-
10). This up-regulation is partly dependent on activation of Akt;
linkage of BVR to Akt-dependent IL-10 synthesis was confirmed
by IL-10 expression being blocked by inhibition of Akt activity
and by siRNA-mediated attenuation of cell surface BVR. Because
BVR is usually considered to be a soluble protein in the cell,
the presence of BVR on the plasma membrane poses the ques-
tion—how did it get there? Transport of BVR to membranes has
been associated with activation of BVR in conjunction with PKCs;
the conventional and atypical PKCs translocate to the membrane
on activation (Newton, 2010, p. 305), and BVR colocalizes with
them (Lerner-Marmarosh et al., 2007; Maines et al., 2007). Asso-
ciation with PI3K, as described in Akt activation (Wegiel et al.,
2009), is another possibility. In addition, some BVR is associated
with caveolae (Kim et al., 2004), whichmay position it for binding
to other membrane proteins.
Conventional and Atypical PKCs
The PKC proteins provide a means of communication to link
signal transduction pathways that respond to extracellular stimuli,
and as such they constitute key control points in those pathways
(Steinberg, 2008; Newton, 2010). The kinases comprise a family
of evolutionarily related proteins that includes three subgroups,
known as conventional, novel and atypical PKCs. Each class is
differentiated by protein structure, mechanism of activation and
function. In addition to the novel PKCd discussed above, BVR
has been shown to activate members of the other PKC classes
(Lerner-Marmarosh et al., 2007; Maines et al., 2007; Gibbs et al.,
2012a).
PKCbII
Both isoforms of PKCb, which arise by an alternate splicing of C-
terminal exons, have been implicated in cancer (Garg et al., 2014).
As indicated in Figure 1, the insulin and IGF1 signaling pathway
is bifurcated. Signals in one arm are transduced via PI3K, while
the other proceeds through the MAPKs. The two pathways do
regulate each other to some extent—as noted, ERK activation sup-
presses Akt activity (Sinha et al., 2004), while Akt phosphorylates
PEA15, which can then sequester ERK in the cytoplasm (Gervais
et al., 2006). Further communication between the two arms is
mediated by the conventional PKCs, including PKCbII; oxidative
stress is a stimulus for PKC activation (reviewed inKoya andKing,
1998; Williams and Tuttle, 2005; Yan et al., 2006). In response
to extracellular stimuli that release diacylglycerol and Ca(II),
the conventional PKCs bind to receptors for activated C-kinase
(RACK) proteins and are translocated to the cell membrane;
RACK1 protein includes a series of tandem repeat sequences that
are involved in PKC binding (Ron et al., 1994). Both PKCb and
BVR have sequence motifs that resemble the RACK1 repeats, i.e.,
the pseudo-RACK sequence SVEIWD (Ron and Mochly-Rosen,
1995) and the human BVR motif, 107AQELWE. It was proposed,
based on these sequence motifs and similar responses of these
proteins to oxidative stress that PKCbII and BVR interact in trans-
duction of insulin signals. As described in greater detail elsewhere,
BVR activates PKCbII by two discrete mechanisms (Maines et al.,
2007; Gibbs et al., 2012b): protein: protein interaction and BVR’s
kinase activity.
First, confocal microscopy was used to demonstrate that after
stimulation with phorbol12-myistate 13-acetate (PMA), BVR and
PKCbII colocalized to the cell membrane (Maines et al., 2007).
Additionally, immunoprecipitates from extracts prepared from
PMA-treated cells included both proteins, indicating a close phys-
ical association that was found to be dependent on both the BVR
ATP-binding site and the cysteine-rich,metal binding sequence in
BVR’s C-terminus. The nucleotide-binding sequence 15GVGRAG
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was essential for activation of PKCbII, as mutation of BVR Gly17
to Ala abolished activation, as did mutating Val11–14. The valine
residues are not expected to interact directly with PKC-bII as they
are not on the exterior of the BVR molecule (Kikuchi et al., 2001;
Whitby et al., 2002); it is likely that the Val11–14 to Ala11–14 muta-
tion destabilizes the BVR secondary structure and thus prevents
binding to PKC-bII.
Second, it was demonstrated that BVR was a substrate for
PKCbII, and vice versa. This relied on the different divalent metal
ion requirements of each kinase. Inclusion of BVR in PKCbII reac-
tion mixtures leads to robust phosphorylation of both proteins
(Maines et al., 2007), while addition of BVR to reaction mix-
tures where the major PKCbII substrate was myelin basic protein
(MBP) increased the Vmax of the PKCbII-MBP phosphorylation
reaction without altering the Km. Maturation of PKCbII requires
the sequential phosphorylation of three sites, the activation loop,
turn and hydrophobic motifs, respectively, located in the C-
terminal catalytic domain (Steinberg, 2008; Newton, 2010). BVR
was capable of phosphorylating a peptide substrate equivalent to
the activation loop of PKCbII, but not peptides based on the turn
and hydrophobic motifs. This does not eliminate the possibility of
phosphorylation by BVRof sites in thematured PKCbII that could
further stimulate its activity.
Because the sequences of the activation loops of PKCs a, b, and
g are very closely related, it is likely that these mechanisms will
also apply to the other members of the conventional PKC family
(a, bI, and g), particularly bI, which is derived from an alternate
splicing event on the PKCbmRNA (Newton, 2010).
PKCz
Biliverdin reductase also activates the atypical PKC, PKCz, which
has been described as promoting pancreatic tumor growth (Butler
et al., 2013), by mechanisms that are similar to the activation of
PKCd. BVR acted as a substrate for PKCz in vitro, with Ser149 or
Ser230 (located in the S/T kinase or an SH2-binding motif, respec-
tively) being the major sites of BVR phosphorylation This PKC
was not a substrate for BVR’s kinase activity (Lerner-Marmarosh
et al., 2007). Addition of kinase-inactive or wild-type BVR to
PKCz-catalyzed kinase reactions stimulated both autophospho-
rylation of the PKC and its activity with a specific substrate. It
is likely that conformational changes in the PKC caused by its
interaction with other proteins leads to its activation in cells.
In cells stimulated by TNF-a, BVR and PKCz formed a com-
plex, as indicated both by their co-immunoprecipitation from cell
lysates and by confocal microscopy (Lerner-Marmarosh et al.,
2007). Activation of PKCz activity in the cell depended on the
presence of BVR; over-expression of BVR resulted in increased
PKCz activity in response to TNF-a, whereas siRNA treatment
significantly inhibited activation. In addition, a peptide contain-
ing the PKCz pseudosubstrate sequence that acts as a competi-
tive inhibitor and siBVR were equally effective in inhibiting the
response to TNF-a. Because downstream signaling events that are
regulated by this PKC include activation of the AP-1 and NF-
kB transcription factors (Moscat et al., 2006), the data indicate
that BVR plays a role in cell signaling pathways, distinct from
the MAPK and PI3K/Akt pathways, that are nevertheless highly
relevant to inflammation and carcinogenesis (Hoesel and Schmid,
2013).
BVR as an Intracellular Transporter
Biliverdin reductase is detected in almost all cell compart-
ments and transports signaling and regulatorymolecules (Lerner-
Marmarosh et al., 2007, 2008; Maines et al., 2007; Gibbs et al.,
2012a) to both the cell membrane and the nucleus using an
energy-dependent process (Tudor et al., 2008). The role of BVR
in transporting kinases to the membrane and nucleus has been
discussed above. However, it apparent that BVR can also transport
heme within the cell, and this process is of importance in regu-
lating transcription of genes that are repressed by the heme- and
DNA-binding protein Bach1.
In mammalian cells, binding of heme to Bach1 dissociates the
repressor from complexes with small Maf proteins (Igarashi and
Sun, 2006) that are associated with specific enhancer regulatory
sequences of genes encoding, for example, b-globin and HO-
1. This allows replacement of Bach1 transcriptional activators
such as NF-E2 p45, or the related Nrf1, Nrf2, and Nrf3, as het-
erodimers with the small Maf proteins. Fluorescence correlation
spectroscopy was used to monitor the diffusion of an EGFP-
BVR fusion protein in cells. It was shown that in untreated cells,
diffusion constants were approximately equal in the cytoplasm
and nucleus (Tudor et al., 2008). In heme-treated cells the rate
of BVR diffusion in the nucleus decreased significantly, which
suggests that BVR’s interactionwith chromatin is enhanced.Heme
was demonstrated to bind to the C-terminal seven amino acids
of human BVR (Tudor et al., 2008), suggesting that the protein
transports heme from the cytoplasm to the nucleus. Treatment
of cells with siRNA to ablate BVR expression or expression of
mutant BVRs lacking either nuclear import or export sequences
blocked HO-1 gene expression after treatment of cells with heme.
BVR most likely modulates the signaling network regulated by
Maf heterodimers and therefore it is likely to aid in expression of
b-globin during differentiation of erythroblasts, and the induction
of HO-1 in response to oxidative stress.
Activation of Transcription
Early response genes, such as c-Fos, c-Jun, ATF2/CREB, and HO-
1 are implicated in carcinogenesis (Lopez-Bergami et al., 2010).
BVR induces their transcription, whether by activating ERK or
more directly. AP1 (Fos-Jun heterodimers) and ATF2/CREB reg-
ulate vascular endothelial growth factor (Vleugel et al., 2006),
to stimulate angiogenesis, which in turn impacts tumor progres-
sion. The primary sequence of human BVR includes a motif
that strongly resembles the conserved motif of the b-Zip class
of transcription factors, and it also possesses canonical NLS and
NES to facilitate transit of the protein between the nuclear and
cytoplasmic compartments. In response to known HO-1 induc-
ers, notably bacterial LPS and bromobenzene, and to cGMP, the
reductase primarily relocated to the nucleus (Maines et al., 2001), a
process requiring a functional NLS. These observations suggested
a role in gene regulation, whichwas subsequently demonstrated in
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several studies. First, dimeric BVR synthesized in rabbit reticulo-
cyte lysate bound to a DNA fragment that included two activator
protein-1 (AP-1) binding sites, derived from the promoter of
the mouse HO-1 gene in a gel-shift assay (Ahmad et al., 2002).
Mutation of residues in the putative leucine zipper motif or using
a target DNAwith fewer copies of the AP-1 site abolished binding.
The effect of overexpression of BVR in cells was studied by
microarray analyses (Kravets et al., 2004); among the genes upreg-
ulated by BVRwas that encodingATF-2/CREB. This transcription
factor is amember of the bZip family, and binds to cAMP response
elements (CRE). It regulates formation of heterodimers of c-Fos
with c-Jun to activate transcription of HO-1 in response to activa-
tion of theMAPK pathway (Kietzmann et al., 2003). HO-1mRNA
levels were also increased in these experiments, as was expression
of reporter genes regulated by either c-Jun (a component of AP-1)
or ATF2. The CRE element was, like the AP-1 elements, a target
for BVR binding as revealed by electrophoretic mobility shift.
The available data, including the slowed nuclear diffusion of BVR
in heme-treated cells (Tudor et al., 2008) indicate that BVR, by
binding elements in the HO-1 promoter/enhancer, functions in
the cell to regulate HO-1 gene transcription.
It is tempting to speculate that BVR acts as a switch in response
to changes in the redox state of the cell; reagents that covalently
bind sulfhydryl groups inhibit its activity, whereas reducing agents
afford protection (Kutty and Maines, 1981) and its activation is
essential for its transcriptional regulation of the stress-responsive
HO-1 gene (Kravets et al., 2004; Miralem et al., 2005; Tudor
et al., 2008). A series of experiments demonstrated that BVR
has a role in the oxidative stress response of the cell. In cells
treatedwith sodium arsenite, a promoter of free radical formation,
increased HO-1 expression was dependent on the presence of
active BVR in the cell (Miralem et al., 2005). Treatment of cells
with siRNA directed against BVR (siBVR) attenuated arsenite-
mediated increases in HO-1 expression and c-jun promoter activ-
ity. BVR, together with AP-1, was present in DNA:protein com-
plexes in the nuclei of arsenite-treated cells. Moreover, down-
regulation of BVR by siRNA led to significant increases in the
number of apoptotic cells after arsenite treatment, accompanied
by increased levels of cellular markers of apoptosis: cytoplas-
mic cytochrome c, cleavage of poly(ADP-ribose) polymerase and
increased expression of the TNF-related apoptosis-inducing lig-
and (TRAIL) proteins and death receptor-5 mRNA.
BVR and the Immune System
Development of cancer depends not only on processes occurring
within the cancer cell, but on interactions with the extracellular
environment. In particular, the immune response of the host
organismmay protect against the developing tumor, or conversely
may provide an environment in which the tumor cells thrive (de
Visser et al., 2006). As noted above, elevated expression of BVR
was detected in infiltrating T-cells, monocytes, macrophages and
lymphocytes seen in human kidney tumors (Maines et al., 1999).
Biliverdin has been shown, inter alia, to be protective in tissue
transplantation, prolonging the survival of xenografts. This pro-
cess, mediated by NF-kB, is likely due to biliverdin/bilirubin/BVR
exerting a dampening effect on the inflammatory response, since
markers of inflammation, such as Cox2 and iNOS, as well as
inflammatory cytokine expression were significantly decreased
in the biliverdin-treated animals (Nakao et al., 2004, 2005). It
is noteworthy that BVR is present in caveolae of the plasma
membrane (Kim et al., 2004), and also on the external surface of
macrophages (Wegiel et al., 2009), suggesting that it may convert
extracellular biliverdin to bilirubin. As noted above, BVR activity
increased rapidly in response to treatment of macrophages with
bacterial lipopolysaccharide, and that extracellular biliverdin was
associated with increased production of IL-10, the prototypical
anti-inflammatory cytokine (Wegiel et al., 2009). SiRNA against
BVR also negated the cytoprotective effects of biliverdin in animal
models of shock and acute hepatitis (Wegiel et al., 2009). It was
subsequently demonstrated that biliverdin induced phosphoryla-
tion of the endothelial nitric oxide synthase (eNOS), which nitro-
sylates BVR (on cysteine) and induces translocation of BVR to the
nucleus (Wegiel et al., 2011). BVR then binds to theAP1 sites of the
Toll-like receptor-4 (TLR4) promoter and represses its transcrip-
tion. This in turn quenches the inflammatory response (Wegiel
et al., 2011). The process is completely dependent on eNOS phos-
phorylation, which is mediated in part by the Ca(II)/calmodulin-
dependent kinase. It is noteworthy that chronic inflammation is a
potentiating factor in cancer development, and tumor-infiltrating
macrophages often predict an unfavorable outcome for cancer
patients (de Visser et al., 2006).
There is also some evidence for BVR playing an indirect role in
he development of autoimmunity. A yeast two-hybrid assay using
BVR as the bait revealed that the Goodpasture antigen-binding
protein (GPBP) was a high affinity binding partner (Miralem
et al., 2010). Goodpasture syndrome is one of several autoimmune
diseases in which GPBP activity is increased, and is characterized
by autoimmune recognition of the C-terminal non-collagenous-1
domain of the a3 chain of type IV collagen (Goodpasture antigen)
in epithelial basement membranes. The deposition of antibodies
in the alveolae results in hemorrhage in the lungs, while their
presence in glomerular basement membranes causes a rapidly
progressive glomerulonephritis (Saus, 1998; Hudson et al., 2003).
GPBP is a non-conventional S/T kinase that recognizes Good-
pasture antigen as a substrate (Raya et al., 1999); its expression is
regulated by TNF-a (Granero et al., 2005). TNF-a also stimulates
the kinase activity of BVR (Lerner-Marmarosh et al., 2007), and
it was demonstrated that BVR binds, via its 281CX10C Zn(II)-
binding motif (Maines et al., 1996), to GPBP, to suppress the
latter’s kinase activity (Miralem et al., 2010). These observations
suggest that BVR suppresses the activity of GPBP, and hence limits
the exposure of the epitope of Goodpasture antigen, thus limiting
autoimmunity.
Antioxidant Production
Increased production of ROS has been considered a hallmark of
many tumors and cancer cell lines. ROS have long been known
to damage proteins, lipids and DNA and are therefore consid-
ered to be capable of promoting genomic instability. Cancer
cells generate increased levels of ROS, and this in turn stimu-
lates signaling pathways that regulate cell proliferation, metabolic
changes and angiogenesis. Biliverdin and bilirubin, the substrate
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and product of BVR’s reductase activity, have been shown to
be antioxidants. It was shown, beginning in the late 1980s, that
the micromolar levels of bilirubin at in plasma, arising from
normal cellular heme turnover protects cells against oxidative
stress-induced injury by acting as a scavenger of ROS (Stocker
et al., 1987; Stocker, 2004; Maghzal et al., 2009; Sedlak et al.,
2009). At higher concentrations, however, free radicals may be
generated by bilirubin; toxicity of bilirubin has been documented
since at least the 1950s. Bilirubin is therefore a double-edged
sword, being either cytotoxic or cytoprotective, depending on
its circulating or tissue concentration, the nature of the stress
to the cell, the tissue or cellular target of that stress, and the
redox status of the stressed cell reviewed by Kapitulnik (2004).
In HeLa cells and mouse embryonic fibroblasts, elevated bilirubin
generated oxidative stress in the form of free radicals and ROS
(Cesaratto et al., 2007). If serum levels of unconjugated bilirubin
are excessive due to increased production and/or decreased con-
jugation, or the blood-brain barrier is not completely matured,
bilirubin enters the brain and binds to specific regions of the brain,
notably the basal ganglia. This causes a spectrum of irreversible
neurological deficits referred to as “bilirubin encephalopathy”
or kernicterus (Shapiro, 2003), with the severity of neurological
symptoms depends on the circulating bilirubin concentration.
Elevated levels of unconjugated bilirubin in cultured neuronal
and astroglial cells results in an array of undesirable metabolic
effects, including altered carbohydrate metabolism and uncou-
pling of mitochondrial oxidative phosphorylation (Kapitulnik,
2004). Inhibition of DNA and protein synthesis, abnormal synthe-
sis and release of neurotransmitters, and apoptosis are also seen
(Kapitulnik, 2004).
It is generally accepted that glutathione (GSH) is a promi-
nent endogenous cytoprotective antioxidant; bilirubin has been
estimated as providing a similar level of protection, with the
two antioxidant systems complementing each other, such that
hydrophilic GSH functioning in the aqueous cytosol and nucleus,
while the lipophilic bilirubin protects membrane lipids (Sedlak
et al., 2009). The cytoprotective functions of bilirubin varies
with context; e.g., bilirubin scavenging of free radicals impairs
bactericidal activity of neutrophils (Overhaus et al., 2006). In
addition, in delayed subarachnoid hemorrhage-induced cerebral
vasospasm, high levels of radicals are produced in thromboses at
the site of hemorrhage. These radicals oxidize bilirubin generating
species that act via PKC-mediated contraction of vascular smooth
muscle cells, resulting in chronic vasoconstriction and vasospasm
reviewed in (Clark and Sharp, 2006). Relaxation of smoothmuscle
is also impaired, due to activation of members of the Rho guano-
sine triphosphatase family leading to inhibition of themyosin light
chain phosphatase (Pyne-Geithman et al., 2008).
Despite the adverse effects of elevated bilirubin levels, there is
evidence favoring a beneficial role of bilirubin acting as a powerful
chain-breaking antioxidant in biological systems (Stocker et al.,
1987; Stocker, 2004; Maghzal et al., 2009; Sedlak et al., 2009).
It has been demonstrated that cells treated with bilirubin are
protected from subsequent treatment with a 104-foldmolar excess
of hydrogen peroxide (Baranano et al., 2002). Bilirubin thus is an
essential contributor to cellular and tissue protection attributed to
increasedHO-1 production; the increased production andnuclear
translocation of HO-1 observed in prostate cancers is likely to
be a mechanism of cytoprotection, given the abnormal redox
status of tumor cells prior to neovascularization (Sacca et al., 2007;
Ferrando et al., 2011, 2013; Biswas et al., 2014).
To account for protective function of bilirubin at what could
be considered catalytic concentrations, it has been proposed that
there is an amplification cycle in which biliverdin is formed by
oxidation of bilirubin and is then reduced by BVR to bilirubin
(Sedlak and Snyder, 2004, 2009). Evidence in favor of the cycle
included the potency of bilirubin as an antioxidant, while elevated
levels of ROS and lipid peroxides which ultimately cause cell death
are observed if cellular BVR is depleted (Baranano et al., 2002;
Sedlak et al., 2009) However, the observed oxidation of bilirubin
to biliverdin is apparently insufficient to support the hypothesis
(Maghzal et al., 2009). The discrepancies have been attributed to
the different methodologies employed (Sedlak et al., 2009), but
there are flaws in the hypothesis that bilirubin can be oxidized
to biliverdin. Two in vitro reactions between bilirubin and alkyl
peroxyl radicals have been suggested (McDonagh, 2010): degra-
dation of bilirubin by peroxyl radicals and oxidation of bilirubin
to biliverdin.However, the latter reaction requires serum albumin,
is independent of peroxyl radical, and is moreover very inefficient
(McDonagh, 2010).
Given the rapid, BVR-catalyzed turnover of biliverdin in vivo,
those studies that claim that biliverdin itself protects cells should
be viewed with some skepticism. Administration of biliverdin
to whole animals attenuates injuries that are induced during
transplantation in a variety of organs including the small intes-
tine, heart and kidney, thereby prolonging survival of transplant
recipients (Nakao et al., 2004, 2005), presumably because of its
anti-inflammatory activity. The survival of cardiac allografts is
prolonged by treatment with biliverdin, resulting in suppression
of both the nuclear factor of activated T-cells (NFAT) and NF-kB
activities (Yamashita et al., 2004). In turn, this inhibits expres-
sion of inflammatory cytokines and slows T-cell proliferation.
It is noted that NF-kB regulates cell proliferation and apop-
tosis (Perkins and Gilmore, 2006). Treatment of cultured cells
treated with biliverdin led to attenuated activation of NF-kB in
response to TNF-a (Gibbs and Maines, 2007); biliverdin did not
bind directly to NF-kB. Conversely, the transcription of NF-kB-
dependent reporters in cells where BVR was over-expressed was
significantly enhanced, whether cells were treated with TNF-a
or not (Gibbs and Maines, 2007). The inflammatory response
depends heavily on the activation of NF-kB, and the activity of
TNF-a, suggesting that BVR and biliverdin are themselves mod-
ulators of inflammation. As noted, the biliverdin induced Akt
signaling and IL-10 expression, mediated by cell-surface BVR and
the in vivo BVR-dependent cytoprotective effects of biliverdin in
animal models of shock and acute hepatitis emphasizes this role
(Wegiel et al., 2009). Furthermore, protection by biliverdin against
acute liver damage in animal model was found to be depen-
dent on the availability of NO, due to biliverdin/BVR-induced
eNOS phosphorylation (Wegiel et al., 2011). S-nitrosylated BVR
is translocated to the nucleus where it binds to AP-1 sites to block
transcription of the TLR4 promoter.
The physiological relevance of bile pigments in cancer develop-
ment also includes their anti-mutagenic properties; being potent
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peroxyl radical scavengers, they inhibit several classes of muta-
gens, including polycyclic aromatic hydrocarbons, heterocyclic
amines, and other oxidants (Bulmer et al., 2007). In the Ames
test, bilirubin and biliverdin were tested in the presence of known
mutagens and found to be anti-mutagenic in the presence of all
mutagens examined except sodium azide (Bulmer et al., 2007),
nor were the bile pigments themselves mutagenic. Subsequently,
it was proposed that exogenous biliverdin and/or bilirubin could
be given as dietary supplements; they would be expected to
be absorbed via epithelial cells of the intestine, leading to ele-
vated antioxidant concentrations in the circulation. This would
be expected to result in a subsequent reduction in the develop-
ment of cardiovascular disease and cancer (Bulmer et al., 2008),
as it is known that both conditions occur at lower frequency
in patients with Gilbert Syndrome, which is characterized by
elevated levels of circulating bilirubin. This would suggest that
administration of bilirubin might be expected to protect against
other ROS-mediated pathologies. For example, atherosclerosis
is inversely correlated with circulating bilirubin concentration
in normal individuals. Ollinger et al. (2007) demonstrated that
proliferation of smooth muscle cells of blood vessels was reduced
in mice treated with bilirubin (and biliverdin), with the result
that narrowing of the vessels was inhibited. Treatment of vas-
cular smooth muscle cells with growth factors in vitro displayed
cell cycle arrest if they were also treated with bile pigments, a
process induced by p53 (Ollinger et al., 2007). Similarly, oral
treatment with biliverdin for 4 weeks slowed the progression of
glucose intolerance and hyperglycemia in diabetic db/db mice
(Ikeda et al., 2011), with concomitant increases in expression
of the pancreatic and duodenal homeobox 1(Pdx1) transcription
factor and insulin content of pancreatic islet cells. Additionally,
these changes were accompanied by normalization of oxidative
stressmarkers and in production ofNADPHoxidase in pancreatic
islets, with a significant reduction in apoptotic cell numbers in the
pancreas.
BVR-based Peptides as Potential Cell
Growth Regulators
Biliverdin reductase has emerged as a protein that supports cell
growth and proliferation due to its role in supporting MAPK
(ERK), PI3K and/or PKC signaling, while also promoting cell
survival by generation of bilirubin. One approach to attacking
the hyperproliferative and tumorigenic phenotype of cancer cells
would be to inhibit the kinase or scaffolding functions of the
reductase, or both. This could be achieved by exploiting the
numerous functional motifs in the primary structure of the pro-
tein. Peptides based on those motifs might be expected to inhibit
BVR function, and thereby provide a means of attenuating cell
signaling and proliferation.
Regulating the activity of BVR and its ability to form com-
plexes with ERK1/2 or PKCd could well be a potential approach
to treatment of those cancers in which ERK1/2 is activated. In
this respect, our studies have offered suggestions that could be
exploited. These are illustrated in Figure 6. Human BVR-based
peptides have been shown to affect not only BVR activity per se,
but also the activities of growth promoting kinases that are major
FIGURE 6 | Peptide inhibition of BVR and ERK1/2.
(A) Autophosphorylation of BVR was determined in reaction mixtures that
included no added peptide or either of the BVR-based peptides KKRILHC or
KRNRYLSF. The products were detected by autoradiography (top) and
quantified by densitometry (bottom). The peptide KRNRYLSF includes a
potential IRK target site. (B) ERK2 kinase reactions with myelin basic protein
as substrate were performed in the presence or absence of the BVR C-Box
(FGFPAFSG) and D-Box (KKRILHCLGL) peptides, which inhibit interaction of
BVR with ERK, *p < 0.01. (C) Peptide FGFPAFSG inhibits ERK-dependent
signaling. Cells were transfected with Elk1 expression plasmid and an
Elk1-dependent luciferase reporter, then treated with myristoylated peptide for
two hours prior to inducing ERK1/2 with IGF-1. After a further 12 h, cells were
harvested and luciferase activity was measured. *p < 0.01 compared to
untreated control. yp < 0.01 compared to IGF-treated.
players in tumorigenesis and are activated by BVR. The peptides
KKRILHCandKRNRYLSF both inhibit the kinase activity of BVR
in vitro (Figure 6A). Because it has not proven possible to date to
separate the kinase and reductase activities of BVR (Salim et al.,
2001), both could have some utility in cancer cells, since they
would block the formation of bilirubin. It is noted above that the
elevated BVR activity in tumors resulted in reduced sensitivity
of cells to chemotherapeutic agents (Florczyk et al., 2011). Over-
coming this barrier might therefore increase the efficacy of such
reagents. Two additional human BVR-based peptides, FGFPAFSG
and KKRILHCLGL, have been shown to inhibit the activity of
ERK1/2 (Figure 6B). These peptides include the C- (Jacobs et al.,
1999) and D-Box (Minden and Karin, 1997) sequences of BVR,
and have been shown to inhibit the formation of the complexes
including BVR, MEK1, and ERK1/2 (Lerner-Marmarosh et al.,
2008) or BVR, PKCd, and ERK (Miralem et al., 2012). By blocking
both upstream activators of ERK, such peptidesmight be expected
to block the activation of downstream targets that lead to cell
proliferation. As shown in Figure 6C the FGFPAFSG peptide
blocks the activation of ERK-dependent signaling in the cell.
Administration ofmyristoylated peptide is impractical in an intact
animal, but other delivery systems, e.g., plasmid expression vec-
tors or nanoparticle systems would be more effective. Another
peptideworthy of note is 230SFHFKSGSL, a potent PKCd inhibitor.
This peptide was found to enhance PMA-induced apoptosis in cell
culture; cells pretreated with peptide for 2 h displayed the mem-
brane blebbing characteristic of apoptosis after a 15min treatment
with PMA (Miralem et al., 2012). The precise mechanisms by
which these peptides act are currently unknown. However, two
other BVR-based peptides have been demonstrated to bind to
IRK and in so doing, alter the secondary structure of the kinase
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(Gibbs et al., 2014), as demonstrated by fluorescence spectroscopy
of dye-tagged IRK. It was noted that the peptides bound to differ-
ent sites; one of the peptides is both a substrate and inhibitor, with
a high affinity for the active site, while the other is an activator that
bound outside the active site to alter the secondary structure.
The potential benefits of peptide inhibition of signaling path-
ways could be offset if they were to display side effects that would
compromise BVR activity in otherwise healthy cells, particularly
those of macrophages or vascular endothelial cells (Wegiel et al.,
2009; Jansen et al., 2010). In both of those systems, biliverdin is a
significant signaling component. However, in the macrophages,
binding of biliverdin to cell-surface BVR is the initiating event
that eventually leads to expression of IL-10. It is not clear whether
this involves reduction of biliverdin to bilirubin. Some of the
peptides examined to date are inhibitors of BVR reductase or
kinase function (Figure 6), but not all. Therefore, off-target effects
of peptides might be limited.
The data obtained with the various peptides therefore offer
the potential for a novel approach to reversing the detrimental
effects of elevated ERK1/2 activity. This would be achieved by
inactivating ERK1/2 directly, or by interfering with formation of
complexes necessary for its activation, translocation within the
cell, or juxtaposition with its targets. It is noteworthy that the
existing data suggest that both known activators, MEK in the
MAPK signaling pathway and PKCd (Ueda et al., 1996; Raman
et al., 2007) are potentially simultaneous targets of the inhibitors.
Concluding Remarks
Biliverdin reductase is a cytoprotective and growth promoting
protein, as a consequence of both its activation of kinases involved
in cell growth, and its being the sole source of the potent anti-
oxidant bilirubin. In addition, it directly activates transcription
of genes involved in the oxidative stress response. Coupled with
increased expression in tumor cells, these properties identify BVR
as a tumor promoter. Recent findings have indicated that many
of BVR’s growth promoting functions could effectively be negated
by use of BVR-based peptides that inhibit its activity and/or its
association with growth-promoting kinases. These peptides offer
a novel approach to slowing the growth of tumor cells.
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